ARQT
Neutral signalScored 2026-10-21 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Arcutis Biotherapeutics, Inc.
- Nom
- Arcutis Biotherapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $3.9B
- Employés
- 354
- PDG
- Todd Franklin Watanabe
- Site web
- https://www.arcutis.com
- Marché
- ACRSALDXEVMNSLGLTTRX
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 9 458 titres (~241 696,44 $ US)
- Insiders
- Welgus Howard G.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,024,420
Avg sell (VWAP, 90d window) $25.55 vs last close $31.81 (+24.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$751,371 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-15
- Liquidity
- Liquid $76,401,757/day · 20d vol
- Last synced
-
2026-10-26 21:10:07
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Welgus Howard G. | Sell · S | 4,728 | $26.93 | $127,325 | Form 4 |
| 2026-09-16 | Matsuda Masaru | Sell · S · 10b5-1 | 3,674 | $25.00 | $91,853 | Form 4 |
| 2026-09-15 | Welgus Howard G. | Sell · S · 10b5-1 | 4,730 | $24.18 | $114,371 | Form 4 |
| 2026-09-08 | Matsuda Masaru | Sell · S · 10b5-1 | 9,989 | $25.03 | $249,986 | Form 4 |
| 2026-08-27 | Curran Terrie | Sell · S | 27,052 | $25.03 | $677,095 | Form 4 |
| 2026-08-20 | Curran Terrie | Sell · S | 1,072 | $26.04 | $27,912 | Form 4 |
| 2026-08-19 | Burnett Patrick | Sell · S | 1,697 | $27.00 | $45,819 | Form 4 |
| 2026-08-17 | Welgus Howard G. | Sell · S · 10b5-1 | 4,730 | $26.18 | $123,835 | Form 4 |
| 2026-08-12 | Burnett Patrick | Sell · S | 6,700 | $26.08 | $174,767 | Form 4 |
| 2026-08-11 | Burnett Patrick | Sell · S | 8,300 | $26.52 | $220,129 | Form 4 |
| 2026-08-03 | Burnett Patrick | Sell · S · 10b5-1 | 955 | $26.12 | $24,942 | Form 4 |
| 2026-08-03 | Matsuda Masaru | Sell · S · 10b5-1 | 1,230 | $26.12 | $32,124 | Form 4 |
| 2026-08-03 | Watanabe Todd | Sell · S · 10b5-1 | 4,375 | $26.12 | $114,261 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-03 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-12-11 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2023-09-15 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2023-04-17 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2022-06-15 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-21 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
ARQT presents a mixed profile: solid liquidity (75) and improving fundamentals (65) are offset by a weak catalyst score (35) driven by insider selling and no confirmed near-term event trigger.
The first sentence of the analysis written for ARQT on 2026-10-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 3.17 · operating margin -3.3% — readings disagree
Suggested stop 25.46, nearest stored support minus 0.5 ATR(19.9% under the last close). Research, not advice. Not an order.
Recent news
- 2026-10-20 Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,728 Shares of Company Stock Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) Director Howard Welgus sold 4,728 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $26.93, for a total transaction of $127,325.04. Following the completion of the transaction, the director owned 35,207 shares in the
- 2026-10-15 Why Is Arcutis Biotherapeutics Stock Surging Thursday? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) stock traded higher Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $48 price forecast, citing strong Zoryve sales growth and expansion opportunities in dermatology.
- 2026-10-09 Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to
- 2026-10-06 Arcutis'' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award Newly created award category highlights innovation in prescription skin treatment ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.15% was presented with the 2026 “Best Prescription Skin Solution” Award by Marie Claire magazine.
- 2026-10-03 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rated “Moderate Buy” by Wall Street Brokerages Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) have earned an average rating of "Moderate Buy" from the nine brokerages that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price
- 2026-10-02 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 62,500 restricted stock units (RSUs) of Arcutis common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis'' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-20 Masaru Matsuda Sells 3,674 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) insider Masaru Matsuda sold 3,674 shares of the business''s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $25.00, for a total value of $91,850.00. Following the sale, the insider directly owned 112,508 shares in the company,
- 2026-09-17 Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last? Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-09-16 Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-04 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 57,000 restricted stock units (RSUs) of Arcutis common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis'' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 90.2% | 90.3% | 91.6% | 79.5% | 0.0% | |
| Ebit Margin | -0.8% | -57.1% | -384.7% | -8025.1% | 0.0% | |
| Ebitda Margin | 0.5% | -55.8% | -383.5% | -7999.8% | 0.0% | |
| Operating Profit Margin | -3.3% | -65.3% | -404.5% | -8183.0% | 0.0% | |
| Pretax Profit Margin | -4.0% | -70.9% | -434.6% | -8449.8% | 0.0% | |
| Continuous Operations Profit Margin | -4.3% | -71.3% | -439.8% | -8449.8% | 0.0% | |
| Net Profit Margin | -4.3% | -71.3% | -439.8% | -8449.8% | 0.0% | |
| Bottom Line Profit Margin | -4.3% | -71.3% | -439.8% | -8449.8% | 0.0% | |
| Current Ratio | 3.167 | 4.145 | 7.080 | 11.569 | 12.086 | |
| Quick Ratio | 2.993 | 3.966 | 6.799 | 11.371 | 12.086 | |
| Solvency Ratio | -0.047 | -0.718 | -1.034 | -1.296 | -1.864 | |
| Cash Ratio | 0.330 | 0.881 | 1.894 | 1.419 | 2.940 | |
| Price To Earnings Ratio | -223.385 | -12.009 | -0.854 | -2.615 | -4.974 | |
| Price To Earnings Growth Ratio | 2.516 | 0.173 | 0.026 | -0.073 | -0.511 | |
| Forward Price To Earnings Growth Ratio | 2.516 | 0.173 | 0.026 | -0.073 | -0.511 | |
| Price To Earnings Diluted Ratio | -223.385 | -12.009 | -0.854 | -2.615 | -4.974 | |
| Price To Earnings Diluted Growth Ratio | 2.516 | 0.173 | 0.026 | -0.073 | -0.511 | |
| Price To Book Ratio | 19.500 | 10.695 | 2.525 | 3.886 | 3.442 | |
| Price To Sales Ratio | 9.825 | 8.573 | 3.756 | 220.964 | 0.000 | |
| Price To Free Cash Flow Ratio | -585.466 | -15.004 | -0.905 | -2.899 | -5.835 | |
| Price To Operating Cash Flow Ratio | -656.867 | -15.023 | -0.906 | -3.160 | -5.868 | |
| Debt To Assets Ratio | 0.014 | 0.317 | 0.603 | 0.451 | 0.190 | |
| Debt To Equity Ratio | 0.033 | 0.702 | 2.322 | 0.966 | 0.261 | |
| Debt To Capital Ratio | 0.032 | 0.412 | 0.699 | 0.491 | 0.207 | |
| Long Term Debt To Capital Ratio | 0.027 | 0.405 | 0.695 | 0.486 | 0.196 | |
| Financial Leverage Ratio | 2.285 | 2.215 | 3.850 | 2.144 | 1.371 | |
| Working Capital Turnover Ratio | 1.403 | 0.730 | 0.174 | 0.010 | 0.000 | |
| Operating Cash Flow Ratio | -0.043 | -1.384 | -5.294 | -6.817 | -5.240 | |
| Operating Cash Flow Sales Ratio | -0.015 | -0.571 | -4.145 | -69.917 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.122 | 1.001 | 1.002 | 1.090 | 1.006 | |
| Debt Service Coverage Ratio | 0.047 | -4.059 | -7.797 | -18.839 | -475.524 | |
| Interest Coverage Ratio | -1.012 | -4.726 | -8.115 | -19.271 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -5.625 | 0.000 | 0.000 | 0.000 | -403.296 | |
| Operating Cash Flow Coverage Ratio | -0.898 | -1.014 | -1.200 | -1.272 | -2.252 | |
| Capital Expenditure Coverage Ratio | -8.200 | -784.322 | -577.236 | -11.069 | -175.505 | |
| Dividend Paid And Capex Coverage Ratio | -8.200 | -784.322 | -577.236 | -11.069 | -175.505 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 2,055.188 | -15.728 | -1.494 | -3.267 | -4.877 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 90.2% | ▼-0.0% | ▲19.9% |
| Ebit Margin | -0.8% | ▲56.3% | ▲1692.8% |
| Ebitda Margin | 0.5% | ▲56.2% | ▲1688.2% |
| Operating Profit Margin | -3.2% | ▲62.1% | ▲1728.0% |
| Pretax Profit Margin | -4.0% | ▲66.9% | ▲1787.9% |
| Continuous Operations Profit Margin | -4.3% | ▲67.0% | ▲1788.7% |
| Net Profit Margin | -4.3% | ▲67.0% | ▲1788.7% |
| Bottom Line Profit Margin | -4.3% | ▲67.0% | ▲1788.7% |
| Current Ratio | 3.167 | ▼-0.978 | ▼-4.442 |
| Quick Ratio | 2.993 | ▼-0.973 | ▼-4.450 |
| Solvency Ratio | -0.047 | ▲0.671 | ▲0.945 |
| Cash Ratio | 0.331 | ▼-0.550 | ▼-1.162 |
| Price To Earnings Ratio | -223.385 | ▼-211.376 | ▼-174.617 |
| Price To Earnings Growth Ratio | 2.516 | ▲2.342 | ▲2.090 |
| Forward Price To Earnings Growth Ratio | 2.516 | ▲2.342 | ▲2.090 |
| Price To Earnings Diluted Ratio | -223.385 | ▼-211.376 | ▼-174.617 |
| Price To Earnings Diluted Growth Ratio | 2.516 | ▲2.342 | ▲2.090 |
| Price To Book Ratio | 19.500 | ▲8.805 | ▲11.491 |
| Price To Sales Ratio | 9.825 | ▲1.252 | ▼-38.799 |
| Price To Free Cash Flow Ratio | -585.466 | ▼-570.462 | ▼-463.444 |
| Price To Operating Cash Flow Ratio | -656.867 | ▼-641.844 | ▼-520.502 |
| Debt To Assets Ratio | 0.015 | ▼-0.302 | ▼-0.301 |
| Debt To Equity Ratio | 0.033 | ▼-0.669 | ▼-0.824 |
| Debt To Capital Ratio | 0.032 | ▼-0.380 | ▼-0.336 |
| Long Term Debt To Capital Ratio | 0.027 | ▼-0.378 | ▼-0.335 |
| Financial Leverage Ratio | 2.285 | ▲0.070 | ▼-0.088 |
| Working Capital Turnover Ratio | 1.403 | ▲0.673 | ▲0.939 |
| Operating Cash Flow Ratio | -0.043 | ▲1.341 | ▲3.712 |
| Operating Cash Flow Sales Ratio | -0.015 | ▲0.556 | ▲14.915 |
| Free Cash Flow Operating Cash Flow Ratio | 1.122 | ▲0.121 | ▲0.078 |
| Debt Service Coverage Ratio | 0.046 | ▲4.105 | ▲101.281 |
| Interest Coverage Ratio | -1.012 | ▲3.714 | ▲5.613 |
| Short Term Operating Cash Flow Coverage Ratio | -5.625 | ▼-5.625 | ▲76.159 |
| Operating Cash Flow Coverage Ratio | -0.898 | ▲0.117 | ▲0.429 |
| Capital Expenditure Coverage Ratio | -8.200 | ▲776.122 | ▲303.066 |
| Dividend Paid And Capex Coverage Ratio | -8.200 | ▲776.122 | ▲303.066 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 2055.188 | ▲2070.916 | ▲1649.224 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.69B | $1.68B | $223.9M | $814.5M | $1.02B | |
| Enterprise value | $3.66B | $1.72B | $341.4M | $963.4M | $1.00B | |
| EV / Sales | 9.73x | 8.77x | 5.73x | 261.36x | 0.00x | |
| EV / Op. cash flow | -650.35x | -15.37x | -1.38x | -3.74x | -5.75x | |
| EV / Free cash flow | -579.66x | -15.35x | -1.38x | -3.43x | -5.72x | |
| EV / EBITDA | 2055.19x | -15.73x | -1.49x | -3.27x | -4.88x | |
| Net debt / EBITDA | -20.59x | -0.36x | -0.51x | -0.51x | 0.10x | |
| Current ratio | 3.17x | 4.14x | 7.08x | 11.57x | 12.09x | |
| Income quality | 0.35x | 0.80x | 0.94x | 0.83x | 0.85x | |
| Graham net-net | $1 | $1 | $1 | $3 | $6 | |
| Tax burden | 107.8% | 100.5% | 101.2% | 100.0% | 100.0% | |
| Interest burden | 518.5% | 124.2% | 113.0% | 105.3% | 100.0% | |
| Working capital | $281.4M | $254.8M | $283.8M | $399.6M | $369.4M | |
| Invested capital | $301.7M | $267.3M | $294.1M | $411.4M | $374.7M | |
| Return on assets | -3.7% | -40.1% | -76.8% | -69.3% | -50.6% | |
| Operating ROA | -3.1% | -37.2% | -61.0% | -70.4% | -58.5% | |
| Return on tangible assets | -3.9% | -41.3% | -78.3% | -70.5% | -50.6% | |
| Return on equity | -8.5% | -88.9% | -295.6% | -148.6% | -69.3% | |
| Return on invested capital | -4.0% | -47.8% | -81.6% | -73.2% | -55.0% | |
| Return on capital employed | -4.0% | -47.9% | -81.8% | -73.3% | -55.1% | |
| Earnings yield | -0.4% | -8.3% | -117.1% | -38.2% | -20.1% | |
| Free cash flow yield | -0.2% | -6.7% | -110.6% | -34.5% | -17.1% | |
| Capex / Op. cash flow | -12.2% | -0.1% | -0.2% | -9.0% | -0.6% | |
| Capex / Depreciation | 14.7% | 5.5% | 57.1% | 2492.8% | 219.2% | |
| Capex / Sales | 0.2% | 0.1% | 0.7% | 631.7% | 0.0% | |
| SG&A / Sales | 73.0% | 116.7% | 310.6% | 3313.2% | 0.0% | |
| R&D / Sales | 20.5% | 38.9% | 185.5% | 4949.4% | 0.0% | |
| Stock comp / Sales | 10.7% | 21.2% | 65.1% | 886.7% | 0.0% | |
| Intangibles / Total assets | 3.4% | 2.7% | 1.9% | 1.6% | 0.0% | |
| Days sales outstanding | 142d | 136d | 158d | 838d | 0d | |
| Days payables outstanding | 125d | 271d | 878d | 4273d | 3517d | |
| Operating cycle | 367d | 413d | 1119d | 4475d | 0d | |
| Cash conversion cycle | 242d | 142d | 242d | 202d | -3517d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years